Hyrax Biosciences

Multi-target panels have emerged as a promising diagnostic tool. With the ability to detect and differentiate multiple pathogens, or multiple genetic markers in one pathogen, these panels represent a compelling advancement in the future of diagnostics. ⚖️ Check out Hyrax Biosciences' blog series to explore the advantages and challenges of implementing these panels. 📰 Keep up to date with our #Exatype multi-target panel product, currently in development. #ComingSoon Read More:

The COVID-19 pandemic has taught us that genomic surveillance is a critical tool in managing disease outbreaks. The WHO’s recent declaration of mpox as a “Public Health Emergency of International Concern.” has thrust the need for genomic surveillance back into the spotlight. Read more here about the urgent need for early action and enhanced surveillance: https://lnkd.in/gyMnrRXD

❄️ Winter is well and truly underway in South Africa! Along with cold viruses and influenza, SARS-CoV-2 continues to circulate in the population. 🧬 Hyrax Biosciences remains committed to supporting SARS-CoV-2 surveillance through #Exatype, our online analysis platform. More than 100 000 samples have been analysed through Exatype since the start of #COVID19! 💬 Dikeledi Kekana, Bioinformatics Scientist at the NICD, recently shared: "Exatype has been instrumental in our analysis of SARS-CoV-2 surveillance throughout the COVID-19 pandemic and now as we continue to monitor the virus". ⏩ Read more here: https://lnkd.in/d_TBF7fw

🚀 NEW Product Launch! Exatype M. TB - an NGS Solution for Mycobacterium Tuberculosis 🤔 To learn more, please join our webinar where we will showcase how #NGS is transforming #Mtb testing worldwide and demonstrate the efficient, comprehensive workflow of #Exatype M. TB.  ℹ At Hyrax Biosciences, we create user-friendly, end-to-end #software #solutions that analyse #DNA seamlessly, transforming complex data to relevant results. Exatype M. TB, incorporates the latest World Health Organization mutation catalogue and generates comprehensive drug-susceptibility reports and lineage-typing results. https://lnkd.in/dbyDCNdM

🆕 We are excited to announce the expansion of our co-marketing agreement with Roche, now including integrated workflows for #HIV, #TB, and #respiratory virus panels.   🤝 This announcement marks a logical progression for the ongoing collaboration between Hyrax Biosciences and Roche. 🗨 "By leveraging our platform to provide robust support for Roche’s KAPA HyperCap M.Tb and respiratory virus panels, as well as their KAPA HyperPETE HIV panel, we not only strengthen our collaboration with Roche but also showcase the remarkable flexibility of our #Exatype platform." (Simon Travers, CEO of Hyrax Biosciences) ⏩ Read more here: https://lnkd.in/dVxWzihs